Blood glucose and HbA1c correlation is central to understanding how well diabetes is being managed. Whilst a blood glucose reading captures sugar levels at a single moment, HbA1c reflects average blood glucose over the preceding eight to twelve weeks — offering a longer-term view of glycaemic control. Together, these two measures complement one another, helping patients and clinicians identify patterns, adjust treatment, and reduce the risk of long-term complications. This article explains how the two tests relate, how to convert between them, what can affect their accuracy, and when to seek advice from your GP or diabetes team.

How Blood Glucose Levels Relate to HbA1c Results

HbA1c reflects average blood glucose over 8–12 weeks because glucose irreversibly binds to haemoglobin; a normal fasting glucose can coexist with an elevated HbA1c if blood sugar is consistently high at other times.

Blood glucose and HbA1c are two distinct but closely related measures used to assess how well blood sugar is being managed, particularly in people living with diabetes. Whilst a blood glucose reading gives a snapshot of sugar levels at a single point in time, HbA1c reflects the average blood glucose concentration over the preceding eight to twelve weeks. Together, they provide a more complete picture of glycaemic control than either test can offer alone.

The relationship between the two is rooted in basic biochemistry. When glucose circulates in the bloodstream, it binds irreversibly to haemoglobin — the protein inside red blood cells — in a process called glycation. The higher the average blood glucose over time, the greater the proportion of haemoglobin that becomes glycated, and therefore the higher the HbA1c result. Because red blood cells have a lifespan of approximately 90 to 120 days, the HbA1c value integrates blood glucose fluctuations across that entire period; however, it is most strongly influenced by glucose levels in the last four to six weeks.

This distinction is clinically important. A person may record a normal fasting glucose on a given morning yet still have an elevated HbA1c if their blood sugar has been consistently high at other times — for example, after meals. Conversely, someone experiencing frequent hypoglycaemic episodes may have a deceptively 'normal' HbA1c that masks dangerous swings in glucose levels. Understanding this correlation helps both patients and clinicians interpret results more accurately and make better-informed treatment decisions. Where there is a notable discrepancy between HbA1c and home glucose or continuous glucose monitor (CGM) readings, this should prompt a review for factors that may be affecting HbA1c reliability (see the section on factors affecting accuracy below).

Understanding HbA1c: What the Test Measures and Why It Matters

HbA1c measures glycated haemoglobin in mmol/mol; in the UK, 48 mmol/mol or above is diagnostic of type 2 diabetes, and sustained elevation is strongly linked to retinopathy, nephropathy, neuropathy, and cardiovascular disease.

HbA1c — formally known as glycated haemoglobin — is measured through a routine blood test and is expressed in millimoles per mole (mmol/mol) in the UK, following the IFCC (International Federation of Clinical Chemistry) standardisation adopted by the NHS. Older percentage-based values (NGSP units) are still sometimes referenced in international literature, but UK laboratories and NICE guidelines use mmol/mol as the standard unit.

According to NICE guidance, the key HbA1c thresholds are:

• Below 42 mmol/mol: Normal range

• 42–47 mmol/mol: Non-diabetic hyperglycaemia (NDH) — sometimes referred to internationally as 'prediabetes'; this indicates an increased risk of developing type 2 diabetes

• 48 mmol/mol or above: Diagnostic of type 2 diabetes (when confirmed on a second test in asymptomatic individuals without acute illness)

Important: when HbA1c should not be used for diagnosis HbA1c is not appropriate for diagnosing diabetes in all situations. It should not be used as a diagnostic test in the following circumstances, where a fasting plasma glucose or oral glucose tolerance test (OGTT) should be used instead:

• Suspected type 1 diabetes (diagnosis should be made urgently on clinical grounds with plasma glucose)

• Children and young people

• Pregnancy

• Acute illness or recent onset of symptoms suggestive of diabetes

• Conditions affecting red blood cell turnover or haemoglobin structure (see the section on factors affecting accuracy)

For people already diagnosed with diabetes, NICE recommends individualised HbA1c targets. For most adults with type 2 diabetes managed with lifestyle measures or metformin alone, a target of 48 mmol/mol is advised. For those on medications that carry a risk of hypoglycaemia — such as sulphonylureas or insulin — a target of 53 mmol/mol is generally recommended to reduce that risk. Targets should always be agreed individually with your diabetes care team.

The test matters because sustained elevated HbA1c is strongly associated with the development of long-term diabetes complications, including retinopathy, nephropathy, neuropathy, and cardiovascular disease. Regular monitoring — typically every three to six months in people with diabetes — allows clinicians to assess whether treatment is effective and to adjust management plans accordingly. It is a cornerstone of diabetes care within the NHS.

Converting Between Average Blood Glucose and HbA1c Values

Estimated average glucose (eAG), derived from the ADAG study, converts HbA1c into mmol/L; for example, HbA1c 48 mmol/mol equates to approximately 7.8 mmol/L average glucose.

For patients who monitor their blood glucose at home using a glucometer or continuous glucose monitor (CGM), it can be helpful to understand how their day-to-day readings relate to their HbA1c result. This is made possible through the concept of estimated average glucose (eAG), which translates HbA1c values into the same units used on home glucose meters (mmol/L in the UK).

The mathematical relationship between HbA1c and average blood glucose is derived from the ADAG (A1c-Derived Average Glucose) study, which established a validated equation linking HbA1c (expressed as a percentage in NGSP units) to average plasma glucose. As a general guide using ADAG/NGSP-aligned values:

• HbA1c 48 mmol/mol (approx. 6.5%) ≈ average glucose of 7.8 mmol/L

• HbA1c 53 mmol/mol (approx. 7.0%) ≈ average glucose of 8.5 mmol/L

• HbA1c 64 mmol/mol (approx. 8.0%) ≈ average glucose of 10.2 mmol/L

• HbA1c 75 mmol/mol (approx. 9.0%) ≈ average glucose of 11.8 mmol/L

These figures are population-based averages and may not precisely reflect an individual's glucose patterns, particularly if they experience significant variability throughout the day or have conditions affecting HbA1c reliability.

Patients using CGM devices may notice that their device displays a 'glucose management indicator' (GMI), which is calculated from average sensor glucose and serves as an approximation of HbA1c. Whilst useful for trend monitoring, GMI is derived from a different equation to eAG and should not be used as a direct substitute for a laboratory HbA1c measurement; the two values may differ, particularly in people with high glucose variability. Discussing both sets of data with your diabetes team provides the most accurate assessment of overall glycaemic control.

Factors That Can Affect the Accuracy of HbA1c Readings

Conditions such as haemolytic anaemia, iron deficiency, haemoglobin variants, pregnancy, and advanced CKD can cause falsely low or falsely high HbA1c results, making alternative measures such as fructosamine or CGM more appropriate.

Whilst HbA1c is a reliable and widely validated test, several physiological and medical factors can affect its accuracy, potentially leading to falsely high or falsely low results. Clinicians and patients should be aware of these limitations when interpreting results.

Conditions that may cause falsely low HbA1c:

• Haemolytic anaemia (increased red blood cell turnover reduces glycation time)

• Recent blood transfusion (introduces new, unglycated red blood cells)

• Haemoglobin variants such as HbS (sickle cell trait) or HbC, which can interfere with some assay methods

• Pregnancy, particularly in the second and third trimesters

• Erythropoietin therapy

• Recent significant blood loss

Conditions that may cause falsely high HbA1c:

• Iron deficiency anaemia (before treatment, as red cells survive longer)

• Vitamin B12 or folate deficiency

• Splenectomy (prolonged red cell survival)

• Severe liver disease

• Marked hypertriglyceridaemia or hyperbilirubinaemia

Chronic kidney disease (CKD): HbA1c may be unreliable in advanced CKD and in people receiving haemodialysis. The direction of bias is variable — results may be falsely low or falsely high depending on the degree of anaemia, red cell survival, and the assay method used. Alternative measures of glycaemic control are generally preferred in this group.

In circumstances where HbA1c reliability is in doubt, alternative measures — such as fructosamine (which reflects average glucose over approximately two to three weeks) or continuous glucose monitoring — may be more appropriate. The NHS and NICE acknowledge that HbA1c should be interpreted in clinical context, and laboratory reports in the UK typically flag results where haemoglobin variants are detected.

It is also worth noting that ethnicity may influence baseline HbA1c levels independently of blood glucose, with some studies suggesting slightly higher HbA1c values in people of African, Caribbean, or South Asian heritage. Current UK diagnostic thresholds are not adjusted by ethnicity, but clinicians are encouraged to consider this when interpreting borderline results.

Using Both Measures Together to Manage Diabetes on the NHS

HbA1c provides a long-term glycaemic overview whilst SMBG or CGM reveals day-to-day patterns; NICE recommends CGM for all adults with type 1 diabetes and structured SMBG where clinically indicated in type 2 diabetes.

Effective diabetes management on the NHS relies on using blood glucose monitoring and HbA1c testing in a complementary fashion. Each measure serves a different clinical purpose, and neither should be viewed in isolation. HbA1c provides the long-term overview, whilst self-monitored blood glucose (SMBG) or CGM data reveals the day-to-day patterns that drive that average.

For people with type 1 diabetes, NICE (NG17) recommends aiming for an HbA1c of 48 mmol/mol or below if achievable without problematic hypoglycaemia. NICE recommends offering CGM to all adults with type 1 diabetes, with a choice of real-time CGM (rtCGM) or intermittently scanned CGM (isCGM) based on individual preference and circumstances. CGM offers real-time glucose data that can be used to fine-tune insulin dosing and identify patterns such as nocturnal hypoglycaemia or post-meal spikes that would not be apparent from HbA1c alone.

For people with type 2 diabetes, routine SMBG is not recommended unless it is clinically indicated — for example, in those using insulin or sulphonylureas, or where hypoglycaemia is suspected. Where SMBG is appropriate, NICE guidance (NG28) supports structured self-monitoring alongside education to help patients interpret and act on their results. NHS diabetes structured education programmes — such as DESMOND for type 2 and DAFNE for type 1 — help patients understand how to use both measures to make informed self-management decisions.

The NHS Annual Diabetes Review, offered to all people with a diabetes diagnosis, includes an HbA1c test alongside other checks such as blood pressure, kidney function, cholesterol, and foot examination. This holistic approach ensures that glycaemic data is considered alongside broader cardiovascular and metabolic risk factors.

When to Speak to Your GP or Diabetes Team About Your Results

Seek prompt advice if HbA1c rises above your agreed target, hypoglycaemic episodes are frequent or severe, or blood glucose is persistently elevated; symptoms of DKA require immediate emergency attention via 999 or A&E.

Knowing when to seek professional advice about blood glucose or HbA1c results is an important aspect of safe self-management. Whilst many fluctuations in blood glucose are expected and manageable, certain patterns or readings warrant prompt contact with your GP or diabetes care team.

Contact your GP or diabetes team if:

• Your HbA1c result has risen above your individually agreed target, or is at or above 58 mmol/mol in type 2 diabetes (a level at which NICE recommends considering treatment intensification), suggesting deteriorating control

• You are experiencing frequent hypoglycaemic episodes (blood glucose below 4.0 mmol/L), especially if these are severe, nocturnal, or occurring without warning symptoms

• Your blood glucose readings are consistently above your agreed target — for example, persistently above 10 mmol/L before meals or above 14 mmol/L at any time — despite following your current treatment plan

• You notice symptoms of hyperglycaemia such as increased thirst, frequent urination, fatigue, or blurred vision

• You are pregnant or planning a pregnancy, as tighter glycaemic targets apply and more frequent monitoring is required

• You have started a new medication that may affect blood glucose, such as corticosteroids

If your blood glucose is persistently high (for example, above 14 mmol/L) or you are feeling unwell, check your blood or urine ketones if you have been advised to do so and have the means to test. Raised ketones alongside high blood glucose may indicate diabetic ketoacidosis (DKA) and require urgent medical attention.

If you experience symptoms of diabetic ketoacidosis (DKA) — including vomiting, abdominal pain, rapid breathing, or confusion alongside high blood glucose — seek emergency medical attention immediately by calling 999 or attending your nearest A&E department.

Not sure if this is normal? Chat with one of our pharmacists →

For urgent queries outside of normal hours, contact NHS 111. For routine advice on interpreting your results or adjusting your monitoring schedule, your GP practice, diabetes specialist nurse (DSN), or local diabetes team can provide guidance. The Diabetes UK helpline (0345 123 2399) can also offer support and information. Many NHS trusts offer digital tools and apps to help patients track and share their glucose data with their care team between appointments.

If you think you have experienced a side effect from a diabetes medicine, you can report this to the Medicines and Healthcare products Regulatory Agency (MHRA) via the Yellow Card scheme at yellowcard.mhra.gov.uk. Reporting suspected side effects helps improve the safety of medicines for everyone.

Frequently Asked Questions